骨癌：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

市場概覽

• 德國骨癌市場預計將從 2025 年的 2,700 萬美元成長到 2035 年的 4,500 萬美元，複合年成長率為 5%，這主要得益於漸進式創新和治療可及性的提高。
• 發病率成長仍然很低（年均複合成長率 1-1.5%），顯示疾病負擔穩定，市場擴張是由治療方法創新驅動的，而不是患者數量的增加。

骨癌概述

骨癌是一種高度侵襲性的惡性骨腫瘤，其特徵是腫瘤梭形細胞產生類似骨的組織，通常發生於青少年長骨的干骺端。由於此腫瘤常伴隨局部疼痛，且夜間加劇，因此需要採取多方面的標準治療方案，包括新輔助MAP化療（胺基甲基葉酸、多柔比星、Cisplatin）、廣泛的手術切除以保留肢體，以及輔助MAP化療。預後取決於是否有組織學壞死和肺轉移。儘管復發病例的生存率幾十年來一直停滯不前，但新的治療策略正在2026年湧現。臨床開發平臺涵蓋了先進的免疫療法，特別關注OST-HER2（一種基於李斯特菌的免疫療法，用於預防肺部復發）的生技藥品許可申請（BLA）的分階段核准以及III期臨床試驗的同步進展。此外，突破性的利沙坦瑞澤替康（HS-20093/GSK5764227）是抗體藥物複合體（ADC），使得使用拓樸異構酶抑制劑的難治性患者能夠實現持續的疾病控制。

在美國，預計新增病例數將從 2025 年的 2000 例增加到 2035 年的 2,200 例，反映出較低的成長率（年複合成長率 1%–1.5%）。

• 這種疾病的負擔源自於確診時轉移率高，以及復發和難治性病例可用的治療選擇有限。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

大公司

• Hansoh BioMedical R&D;Company
• MedPacto, Inc.
• Emerald Clinical Inc.
• Tcelltech Inc.
• Circle Pharma
• Cellectar Biosciences, Inc.
• Jazz Pharmaceuticals
• Inhibrx Biosciences, Inc
• Valo Therapeutics Oy
• Amgen
• Eli Lilly and Company
• Shanghai Pharmaceuticals Holding Co., Ltd
• GlaxoSmithKline
• Hangzhou DAC Biotechnology Co., Ltd.
• Iovance Biotherapeutics, Inc.
• USWM CT, LLC
• UNICANCER
• Valent Technologies, LLC
• SEED Therapeutics, Inc.
• Actuate Therapeutics Inc.
• Pfizer
• Merck Sharp &Dohme LLC
• Endeavor Biomedicines, Inc.
• Hoffmann-La Roche

目錄

第1章：主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者群體
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要治療方法－概述及關鍵意見領袖見解
• 新興治療方法
• 重點
• 值得關注的後期新興治療方法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興治療方法。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Global Osteosarcoma Market Outlook

Thelansis's "Global Osteosarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Osteosarcoma treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Osteosarcoma Overview

Osteosarcoma is an aggressive malignant bone tumor characterized by osteoid production by neoplastic spindle cells, typically arising in long bone metaphyses of adolescents. Localized pain with nocturnal worsening mandates a multimodal standard of care: neoadjuvant MAP chemotherapy (methotrexate, doxorubicin, cisplatin), wide limb-salvage surgical resection, and adjuvant MAP. Prognosis depends on histologic necrosis and pulmonary metastases. For decades, relapsed disease had stagnant survival rates, but the 2026 landscape features novel therapeutic strategies. The clinical pipeline integrates advanced immunotherapies, highlighted by the rolling BLA and Phase III trial alignment of the Listeria-based immunotherapy OST-HER2 to prevent pulmonary recurrence. Additionally, the breakthrough deployment of the B7-H3-directed antibody-drug conjugate risvutatug rezetecan (HS-20093/GSK5764227) leverages topoisomerase payloads to establish durable disease control in refractory cohorts.

In the United States, incident cases are projected to increase from 2.0K in 2025 to 2.2K by 2035, reflecting a low growth rate (1-1.5% CAGR).

• Disease burden is driven by: High rates of metastasis at diagnosis & Limited treatment options in relapsed/refractory settings

Market Overview

• The osteosarcoma market in Germany is projected to grow from $27M in 2025 to $45M by 2035, reflecting a CAGR of 5%, driven by incremental innovation and improved treatment access.
• Incidence growth remains low (1-1.5% CAGR), indicating: Stable disease burden & Market expansion driven by treatment innovation rather than patient volume

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Hansoh BioMedical R&D Company
• MedPacto, Inc.
• Emerald Clinical Inc.
• Tcelltech Inc.
• Circle Pharma
• Cellectar Biosciences, Inc.
• Jazz Pharmaceuticals
• Inhibrx Biosciences, Inc
• Valo Therapeutics Oy
• Amgen
• Eli Lilly and Company
• Shanghai Pharmaceuticals Holding Co., Ltd
• GlaxoSmithKline
• Hangzhou DAC Biotechnology Co., Ltd.
• Iovance Biotherapeutics, Inc.
• USWM CT, LLC
• UNICANCER
• Valent Technologies, LLC
• SEED Therapeutics, Inc.
• Actuate Therapeutics Inc.
• Pfizer
• Merck Sharp & Dohme LLC
• Endeavor Biomedicines, Inc.
• Hoffmann-La Roche

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)